^
Association details:
Biomarker:KMT2D mutation
Cancer:Non Small Cell Lung Cancer
Drug Class:PD1 inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy

Published date:
12/17/2022
Excerpt:
Herein, the pTMB and genetic alterations were investigated as predictive biomarkers for anti-PD-1 monotherapy outcome in metastatic non-small cell lung cancer (NSCLC)....PFS was prolonged in patients with immune checkpoint inhibitors (ICIs)-sensitive markers such as ARID1A, KMT2D, and LRP1B alteration...
DOI:
https://doi.org/10.1177/17588359221141761